Dr. Sankhala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9100 Wilshire Blvd Ste 840w
Beverly Hills, CA 90212Phone+1 424-777-0708Fax+1 424-421-2522
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2010 - 2012
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2010
- Dr. S.N. Medical CollegeClass of 1997, MBBS
- U Texas HSC
- Institute for Drug Development
Certifications & Licensure
- TX State Medical License 2011 - 2026
- CA State Medical License 2011 - 2025
- American Board of Internal Medicine Medical Oncology
- American Board of Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- AACR-NCI Scholarship for “Molecular Biology in Clinical Oncology” workshop AACR-NCI, 2007
- The American Society of Clinical Oncology Foundation Merit Award ASCO, 2005
Clinical Trials
- Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor Start of enrollment: 2015 Jun 01
Publications & Presentations
PubMed
- 1 citationsPilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.Santosh Kesari, Naveed Wagle, Jose A Carrillo, Akanksha Sharma, Minhdan Nguyen
Clinical Cancer Research. 2024-01-17 - 25 citationsCombined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination.Sol Lee, Kamalesh K Sankhala, Swaraj Bose, Ron P Gallemore
International Medical Case Reports Journal. 2022-01-01 - 19 citationsA Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla
Clinical Cancer Research. 2021-09-13
Committees
- Board Member, Institutional Review Board (IRB) 2018 - 2020
- Board Member, Disease Research Group 2017 - 2020
- Board Member, Protocol Review and Monitoring Committee 2017 - 2018
- Member, Pharmacy Utilization Management Committee 2011 - 2013
Professional Memberships
- Member
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: